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TITLE OF CASE 
Acute renal transplant rejection following nivolumab therapy for metastatic melanoma 
SUMMARY 
Background: Cancers can develop the ability to evade immune recognition and destruction. 
Immune checkpoint inhibitors (ICIs) are drugs targeting these immune evasion mechanisms. ICIs 
have significantly improved outcomes in several cancers including metastatic melanoma. 
However, data on toxicities associated with allograft transplant recipients receiving ICI is limited. 
Case: We describe a case of a 71-year-old female who was diagnosed with metastatic melanoma 
13 years after renal transplantation. She was commenced on the immune checkpoint inhibitor 
Nivolumab. She developed acute renal transplant rejection 15 days after administration of the 
first dose. She continues on haemodialysis but has demonstrated complete oncological 
response. 
Discussion: This case demonstrates the risk of acute renal transplant rejection versus improved 
oncological outcomes. Patients and clinicians must consider this balance when initiating ICI 
therapy in allograft transplant recipients. Patients should be fully consented of the potential 
consequences of acute renal transplant rejection including life-long dialysis.  
This article has been accepted for publication in BMJ Case Reports (2021) following peer review, and the Version of Record can be 
accessed online at [http://dx.doi.org/10.1136/bcr-2020-238037.
BACKGROUND 
Allograft transplant recipients commonly receive immunosuppressive drugs to reduce the risk of 
transplant rejection. These drugs decrease immunosurveillance and result in activation of 
oncogenic viruses, contributing to an increased risk of developing cancer.[1] Examples of such 
viruses include the human papillomavirus, Ebstein-Barr virus, hepatitis B virus and hepatitis C 
virus.[2] It is estimated that renal transplant recipients have a 3-5 times increased risk of 
developing lung cancer, colorectal cancer, melanoma and non-melanoma skin cancers, 
particularly squamous cell cancer.[3][4] 
 
In addition to the original six Hallmarks of Cancer, Hanahan and Weinberg subsequently 
described the evasion of immune destruction as a further hallmark.[5] In a healthy individual, 
cytotoxic natural killer cells and T cells are responsible for the recognition of, and subsequent 
immune response against tumour cells.[6] However, some cancers develop mutations granting 
the ability to evade immune recognition and consequent immune-mediated apoptosis.[7] 
Upregulated expression of programmed cell death ligands (PD-L1 and PD-L2) have been 
observed in several cancers including melanoma.[3] These ligands bind to PD-1 receptors on T-
cells and cause T-cell inhibition. Similarly, an increased expression of cytotoxic T lymphocyte-
associated antigen-4 (CTLA-4) on cancer cells can result in the inhibition of T-cell function.[8] 
With this protection from the immune system, cancer cells can proliferate unchecked.  
 
Immune checkpoint inhibitors (ICIs) are anti-cancer therapies that target these immune cell 
recognition pathways. Nivolumab and  pembrolizumab are monoclonal antibodies that bind to 
the PD-1 receptor on T-cells, preventing its interaction with PD-L1 and PD-L2 ligands on cancer 
cells. This inhibits the ability of a cancer cell  to evade recognition by host T-cells.[9][10] 
Ipilimumab is another monoclonal antibody that blocks CTLA-4 signalling, allowing physiological 
T-cell responses.[11]  
 
ICIs have revolutionised the treatment of several cancers including metastatic melanoma. Both 
single agent and combination therapy are effective in this setting, with five-year survival 
reported as 52% in the CheckMate 067 study of combination ipilimumab with nivolumab.[12]  
 
However, the use of ICIs is associated with immune-mediated adverse reactions (IMARs). These 
adverse reactions can be organ-specific or organ non-specific. Organ-specific toxicity can 
resemble autoimmune disease and is due to an enhanced activity of the immune system. 
Examples of such reactions include endocrinopathies, colitis, , nephritis and 
pneumonitis.[13][14][15] The risk and consequences of IMARs are more significant in allograft 
transplant recipients. The stimulation of immune activity caused by ICIs increases the risk of the 
transplanted organ being recognised as foreign This can ultimately lead to transplant rejection. 
Therefore, care must be taken when considering ICI therapy in allograft transplant recipients.  
 
We present a case from our unit where a renal transplant recipient opted to receive an ICI 




A 71-year-old female with renal failure secondary to primary chronic pyelonephritis received a 
living unrelated donor kidney transplant in 2003.  Her immunosuppressant therapy for 
transplant rejection prevention was mycophenalate mofetil, tacrolimus and prednisolone at this 
time.  
 
She then presented with  an enlarging non-ulcerating left scalp lesion in 2016. This was 
subsequently diagnosed as a Breslow thickness 1.6mm superficial spreading malignant 
melanoma. She underwent a wide local excision, burring of outer cortex of skull and split skin 
grafting in the same year. Due to the location of the lesion, the medical team decided not to 
perform a sentinel lymph node biopsy at this stage.   
 
In October 2017, she was diagnosed with a second melanoma – on this occasion  an ulcerating 
Breslow thickness 2.3mm lentigo maligna melanoma on her left temple. This was also excised. A 
staging computed tomography (CT) scan at this time showed a nodule of unknown significance 
in the left lung upper lobe. Another CT scan 4 months later demonstrated 2 new coalescent 
nodules in the right lung middle lobe while the left lung upper lobe nodule from the previous 
scan remained unchanged. Her case was reviewed at the local tumour board and the consensus 
was that this  was likely in keeping with metastatic spread from a melanoma primary. Therefore, 
she did not have a biopsy of the lung lesions or a PET-CT at this stage and the decision was made 
to monitor closely with repeat imaging. 
 
In July 2018, the patient developed left neck lymphadenopathy. A new 1.2cm malignant level V 
neck node and a new 6mm left lung lower lobe nodule suspicious for metastasis was noted on 
repeat CT scan. Her previously noted lung lesions were stable. She underwent a left neck levels 
II-V nodal dissection. 3 of the 55 dissected lymph nodes tested positive for metastatic melanoma 
which was wild type for BRAF, Kit and NRAS. At this stage, her immunosuppressant therapy 
consisting of mycophenalate mofetil, tacrolimus and prednisolone was reduced to tacrolimus 
(1.5mg, twice daily) and prednisolone (5mg, once daily) in an attempt to slow disease 
progression.  
 
In November 2018, she then developed 4 nodules on her scalp. These nodules were completely 
excised, with 2 of the nodules showing recurrence of melanoma. BRAF testing was discussed at 
the local tumour board but it was felt that the recurrence was consistent with the surgical 
specimen 4 months prior; BRAF re-testing was therefore not re-performed. Systemic treatment 
with the PD-1 inhibitor  nivolumab for metastatic melanoma was considered at this point. As the 
patient was clinically well,  with a slow rate of disease progression and ICI therapy would  
potentially have a high risk of renal transplant rejection, the decision was taken to manage 
conservatively and observe closely after discussion with the patient.  
 
However, by May 2019, the patient had further disease progression with new scalp nodules, an 
enlarged parotid lymph node and an increased number and size of pulmonary nodules. As the 
disease was gathering pace, it was  agreed to commence ICI therapy in the form of  nivolumab, 
480mg every 4 weeks.  
 
Prior to commencing immunotherapy, her baseline creatinine was 100umol/L and urea was 
7.5mmol/L. 15 days after the 1st dose of treatment, she developed oliguria, shortness of breath, 
bilateral pedal oedema and a 3kg weight gain. Blood tests showed that creatinine had risen to 
392umol/L and urea to 19.2mmol/L (Figure 1), corresponding to acute kidney injury stage 3. The 
patient was diagnosed with acute renal transplant rejection and commenced on haemodialysis. 
Her tacrolimus was stopped but she remained on prednisolone to reduce symptoms of 
transplant rejection.  
INVESTIGATIONS If relevant 
NA 
 




TREATMENT If relevant 
NA 
OUTCOME AND FOLLOW-UP 
The patient continued with her nivolumab regime post-transplant rejection. Imaging after 7 
cycles of nivolumab therapy showed complete response to therapy with a resolution of the 
pulmonary nodules (Figure 2) and resolution of the 2 scalp nodules (Figure 3 and Figure 4). This 
response is ongoing. She did not experience any adverse skin effects during her nivolumab 
treatment. Interruption of her therapy was discussed at length, but the patient expressed her 
wish to continue receiving her therapy. She will complete a 2-year course of nivolumab in March 
2021. She remains on low-dose prednisolone and 3-times-a-week haemodialysis.  
DISCUSSION Include a very brief review of similar published cases 
Before the introduction of ICIs, prognosis for advanced melanoma was poor. Patients treated 
with dacarbazine and interleukin-2 had a median overall survival (mOS) of 11.2months and 
19.6months respectively.[16][17] However,  trials have proven the higher efficacy of ICIs in the 
management of melanoma.  
 
The CheckMate 067 trial demonstrated that for patients receiving nivolumab alone for stage III 
or IV melanoma (with or without BRAF mutations), the overall 5-year survival was 44% and  mOS 
was 36.9months.[12] The same trial also demonstrated that for patients receiving the 
combination of nivolumab with ipilimumab, the mOS was 60.0months and the overall 5-year 
survival was 60% in tumours with BRAF mutation and 48% in tumours without BRAF mutation. 
The combination arm was associated with significantly higher levels of IMARs. 22% of these 
patients had complete oncological response, 36% had partial response and 12% had stable 
disease.[12] The KEYNOTE-001 trial demonstrated that  pembrolizumab alone in 
advancedmelanoma achieved a mOS of 23.8months and an overall 5-year survival of 34%. 16% 
of patients in this trial had complete response, 25% had partial response and 24% had stable 
disease.[18] Studies comparing nivolumab with pembrolizumab have shown a mOS of 
23.9months with nivolumab compared to 22.6months with pembrolizumab [19] 
 
The aforementioned trials excluded transplant recipients in their study, and therefore data on 
toxicities in this patient group is derived primarily from case reports and series.   
 
We describe a case of acute renal transplant rejection requiring dialysis after commencement of 
nivolumab for metastatic melanoma. The onset of rejection was approximately 15 days post 
cycle 1, despite ongoing tacrolimus and prednisolone immunosuppression. The patient has 
subsequently had complete oncological response and continues on her nivolumab therapy. This 
case adds on to a growing number of cases involving renal transplant recipients receiving ICI 
therapy for metastatic melanoma. Table 1 compares our case with other previously reported 
cases.  
 
A study by Manohar et al. showed that 8/18 (44.4%) renal transplant recipients treated with 
nivolumab alone experienced rejection. This was compared to 3/18 (16.6%) patients who were 
treated with  pembrolizumab alone and 2/18 (11.1%) with ipilimumab alone. Median time from 
ICI initiation to acute renal transplant rejection in this study was 24 days.  Of these 18 patients 
whom developed acute renal transplant rejection after ICI therapy, 9 (50.0%) patients had 
favourable response (stable disease, partial response and complete response) while 7 (38.9%) 
patients had progressive disease. This is compared to patients whom did not develop acute 
renal transplant rejection after ICI therapy where 11/25 (44.0%) had favourable response and 
14/25 (56.0%) had progressive disease.[28] The connection between oncological response and 
incidence of IMARs as shown by this study has similarly been demonstrated by Indini A et al. This 
study correlated the incidence of IMARs with improved progression free survival. Median overall 
survival for patients who experienced IMARs was 21.9months, as compared to 9.7months in 
patients who did not experience IMARs.[29] 
 
Fisher et al. reported that 7/11 (64%) patients experienced acute renal transplant rejection 
when treated with nivolumab alone. 2/8 (25%) acute renal transplant recipients treated with 
pembrolizumab and another 2/8 (25%) treated with ipilimumab alone also had acute renal 
transplant rejection.[30]  
 
Another study by Smedman et al. showed that 4/7 (57.1%) renal transplant recipients treated 
with PD-1 inhibitor alone had acute transplant rejection. This was the same for 1/3 (33.3%) renal 
transplant recipients treated with ipilimumab alone.[31]  
 
Abdel-Wahab et al. demonstrated that 2/5 (40.0%), 4/9 (44.4%) and 2/4 (50.0%) renal transplant 
recipients had acute transplant rejection when treated with Nivolumab,  pembrolizumab and 
ipilimumab alone respectively.[29] The median time from ICI initiation to acute renal transplant 
rejection were 18.5 days for nivolumab alone, 21 days for  pembrolizumab alone and 21 days for 
ipilimumab alone.[32]  
 
 Our patient’s experience follows closely with the results of the above studies. The higher 
incidence of acute transplant rejection associated with nivolumab demonstrated by the studies 
corresponds with the acute transplant rejection in our patient after nivolumab initiation. Our 
patient also had complete oncological response, tallying with the higher percentage of patients 
having both  IMARs and favourable oncological response. Our patient developed acute 
transplant rejection 15 days after ICI initiation, similar to the 18.5 days demonstrated by Abdel-
Wahab et al.   
 
Since the decision to continue treatment was made, new evidence has been published showing 
the efficacy of interrupting treatment early in patients achieving complete oncological response. 
The KeyNote-006 trial demonstrated that patients who achieved complete oncological response 
and received 2 years of pembrolizumab treatment had an estimated 24-month progression free 
survival (PFS) of 85.4%. In those who achieved complete oncological response but received less 
than 2 years of pembrolizumab (6 months of pembrolizumab and 2 additional doses after first 
scan showing complete response) PFS was 86.4%.[33] This highlights the durability of response 
in patients who have a complete oncological response and provides reassurance to clinicians 
and patients about treatment interruption if required.  
 
In summary, patients with organ transplants appear to have a high chance of organ rejection 
with use of ICI, but this comes with a greater chance of oncological response. This case and the 
other published reports highlight the importance of an individualised discussion with each 






Age Sex Kidney disease  Kidney transplantation  
Melanoma diagnosis  
(year diagnosed)  
Site of metastases 
(year diagnosed)  
Immunosuppression 















71 F Chronic primary 
pyelonephritis 
2003 1.6mm superficial 
spreading melanoma 
(2016) 





15d Ongoing Complete 
response  
Ong et al.[20] 63 F Hypertension and 
diabetes mellitus 
2004 2.59mm melanoma Lung and hilar lymph 
nodes 
Prednisolone  Acute T-cell 
mediated 
rejection  




60 F Polycystic kidney 
disease 
2003 Metastatic melanoma 
(2014) 





No rejection NIL 4 doses Disease 
progression 









73 M NR  NR  Superficial spreading 
melanoma 
NR  Everolimus  Acute T-cell 
mediated 
rejection  







58 M Hydronephrosis 1982 Uveal melanoma (2013) Lung, liver and bone 
(2015) 
Cyclosporine No rejection  NIL 4 doses Disease 
progression   
Kwatra et 
al.[24] 
58 M IgM nephropathy  2001 21mm ulcerated 
nodular melanoma  
Liver, bone, hilar lymph 
nodes and porta 
hepatis lymph nodes 
Azathioprine and 
everolimus  
Rejection  42d 2 doses Disease 
progression   
Tio et al.[22] 70 M NR NR  Metastatic melanoma NR  Tacrolimus and 
prednisolone 
No rejection  NIL NR  Disease 
progression  
Tio et al.[22] 75 M NR  NR  Metastatic melanoma NR  Prednisolone No rejection  NIL NR  Partial 
response 
Tio et al.[22] 65 M NR  NR  Metastatic melanoma NR  Prednisolone, 
mycophenalate mofetil, 
tacrolimus 




58 M Hydronephrosis 1982 Uveal melanoma (2013) Lung, liver and bone 
(2015) 
Cyclosporine No rejection  NIL 4 doses Disease 
progression   




72 M Hypertension 2000 8mm ulcerated 
melanoma (2008) 
Left axillary lymph 
nodes 
Prednisolone No rejection  NIL NR  Complete 
response  
Lipson at al.[25] 58 M Polycystic kidney 
disease 
2004 4.2mm nodular 
melanoma (2011) 
Lung, right neck lymph 
nodes and mesenteric 
lymph nodes 
Prednisolone  No rejection  NIL 4 doses Disease 
progression  
Jose et al.[26] 40 M NR  1997 Ocular melanoma 
(2013) 
Liver (2013) Prednisolone Acute T-cell 
mediated 
rejection  
NR  2 doses Disease 
progression  
Zehou et al.[27] 67 M Nephroangiosclerosis   
and diabetes mellitus 
2012 Metastatic melanoma 
(2014) 
Lymph nodes Everolimus No rejection  NIL 4 doses Disease 
progression   
Zehou et al.[27] 57 F Polycystic kidney 
disease 
2007 Lentigo malignant 
melanoma (2010) 
Lymph nodes Sirolimus and 
prednisolone 
No rejection  NIL NR  Disease 
progression   
Zehou et al.[27] 68 F Polycystic kidney 
disease 




No rejection  NIL 2 doses Disease 
progression  
Table 1: Case reports of renal transplant recipients receiving ICI therapy for metastatic melanoma. NR=Not reported   
 
LEARNING POINTS/TAKE HOME MESSAGES 3-5 bullet points 
• Immune checkpoint inhibitor therapy has greatly improved metastatic melanoma outcomes.  
• Renal transplant recipients risk acute renal transplant rejection when receiving immune 
checkpoint inhibitor therapy.  
• Clinicians must consider the risk of acute renal transplant rejection alongside the benefit of 
improved oncological outcomes with immune checkpoint inhibitors.  
• Patients should be fully consented of the potential consequences of acute renal transplant 
rejection including life-long dialysis before deciding to initiate ICI therapy.  
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Figure 1: Changes in Creatinine from baseline to post-acute renal transplant rejection  
 
Figure 2: CT scan of the lungs before Nivolumab (A) and after 7 cycles of Nivolumab (B). A 15mm lung 
nodule in the left lung lower lobe (arrowed) has resolved within this period.  
 
Figure 3: CT scan of the head before Nivolumab (A) and after 7 cycles of Nivolumab (B). A 22mm lesion in 
the left occipital region (arrowed) has resolved with some scarring within this period.  
 
Figure 4: CT scan of the head before Nivolumab (A) and after 7 cycles of Nivolumab (B). A 6mm lesion in 




Q: How was your journey from the very beginning, from the melanoma diagnosis? 
A: I wasn’t frightened at the initial diagnosis of the melanoma; it was very quickly cut out from 
the top of my scalp. I was only really worried when it spread to my lymph nodes, worried that it 
might have spread elsewhere. It was also scary when my neck blew up after the operation and 
when I went to the ICU. I was a bit more assured when the doctors told me that only 3 out of 55 
of the lymph nodes were infected. I was initially told that I had 3 to 6 months to live if I didn’t go 
for the immunotherapy. I still wanted to be around with kids and it felt like there was no choice 
but to go for the immunotherapy.  
There was some trauma with the rejection, but I was aware and open to dialysis. I felt that it was 
an acceptable risk compared to only having 3 to 6 months to live. There is some regret about the 
rejection with how I’m living my life now, mainly because of the breathlessness. I can’t walk 
short distances anymore without feeling breathless and needing to sit down. It’s definitely 
lowered my quality of life a bit, but I am very thankful for my husband for helping me around. 
Just last week I had around 1.5 litres of fluid drained from my lungs. This was after the doctors 
were trying to drain fluid everywhere else that was not there. I felt much better after taking off 
the fluid, but I feel that it’s coming back again. 
I am not someone who thinks too much of the future, I prefer to take it one day at a time and 
live in the now, but there is definitely some anxiety of the unknown. 
My brother died of neck cancer, back when there was no immunotherapy. I thought that it was 
really scary and I didn’t want to go through it without trying the immunotherapy. I see 
immunotherapy as hope. 
 
Q: Would you ‘recommend’ immunotherapy to people like you? 
A: Yes, I would ‘recommend’ it. The diarrhoea I had was problematic but bearable in the end. I 
think I was very lucky with the side effects in the way that it’s not as bad as some people. 
 
Q: How would you describe your journey? 
A: Definitely rocky with its up and downs 
 
Q: If you were to go back to 2016, back to the beginning, would you have done anything 
differently? Would you have asked for anything differently? 
A: Not at all. I am very happy with the care I have been provided, the staff and my entire 
journey. I’ve got no complains whatsoever. And no, I don’t think I would have done anything 




Q: Do you feel that the rejection was worth it? 
A: Yes, it was worth the rejection. I am ok with the dialysis 3 times a week; I am managing well 
with this”  
 
Q: What went through your mind during the period of rejection? 
A: I thought it was over and I actually wished it was over; I wasn’t sure I was able to cope with it 
anymore, with one thing coming after another.”  
 
Q: What are your prospects for the future from today onwards? 
A: I’m hoping to continue to get away on weekends, go for walks once in a while. I am very lucky 
to have my husband who pushes me, encourages me, and who is a good support. I want to 
continue getting hugs from my grandchildren. Life is too short to give up. I have a tremendous 
amount of support too from my faith. It may be silly to some people the amount of support I get 
from my faith, but it is very important to me. 
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